Compare Adaptive Biotechnologies Corp (ADPT) vs Match Group Inc (MTCH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Match Group Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.25 (market cap $3.33B), while Match Group Inc trades at $38.16 (market cap $9.14B). The key difference: Match Group Inc is far larger — about 2.7× Adaptive Biotechnologies Corp's market cap, and Match Group Inc pays a 2.04% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | MTCH | |
|---|---|---|
Market Cap | $3.33B | $9.14B |
Sector | Health | Media |
52-Week High | $22.37 | $39.18 |
52-Week Low | $10.24 | $28.90 |
Enterprise Value | $3.19B | $12.09B |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
MTCH trades at $39.18, up 3.38% in the last session, with a bullish technical signal and consistent earnings beats. The stock shows strong fundamentals with a 73.8% gross margin and 18.83% net income margin, supported by positive cash flow trends. Recent news highlights a turnaround narrative, with Tinder stabilizing and Hinge driving growth.
Outlook is positive with a consensus price target of $41.63, implying 6.3% upside. Risks include high debt levels and user decline concerns. Analysts are bullish (53% buy ratings), but investors should monitor execution on growth initiatives amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
